Asceletis’ muscle-preserving weight loss therapy sustains 40-day half-life
Ascletis Pharma’s Phase Ib trial examining its adipose-targeted muscle-preserving weight loss candidate has been able to show a half-life of …
-
-
Seismic Therapeutic doses first healthy participant cohort in Phase I trial of S-1117
US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase I trial of …
-
OSE announces overall survival success in Phase II PDAC vaccine trial
OSE Immunotherapeutics’s Phase II trial examining its neoepitope-based therapeutic cancer vaccine Tedopi (OSE2101) in patients with pancreatic ductal adenocarcinoma (PDAC) …
-
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human immunodeficiency virus …
-
Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR
US-based biotechnology company Biogen has begun dosing in the Phase III TRANSCEND trial to assess felzartamab in adult kidney transplant …
-
Hansa Biopharma enrols all subjects in imlifidase trial for kidney transplants
Swedish biotechnology company Hansa Biopharma has finished enrolling subjects in a Phase III trial in Europe evaluating survival rates among …
-
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed …
-
Singapore’s SGI announces JV to expedite financing for clinical trials
Singapore-based SPRIM Global Investments (SGI) and One Investment Management (OneIM) have announced a $300m joint venture (JV) to expedite financing …
-
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
Johnson & Johnson (J&J) and Protagonist Therapeutics’s joint interleukin-23 (IL-23) inhibitor, icotrokinra, has met the primary endpoint in a Phase …
-
Trevi’s Phase IIb chronic cough success spikes stock by 71%
Trevi Therapeutics’ stock value has shot up more than 53% after its investigational therapy Haduvio (nalbuphine hydrochloride) reduced the frequency …
-
Clario to acquire eCOA operations of WCG
Endpoint data solutions provider Clario has signed a definitive agreement for acquiring the electronic clinical outcomes assessments (eCOA) business of …
-
Amid deglobalising trade, experts seek AI safeguards for clinical trial supply
The role of AI in supply chain management proved to be the focal issue at the recent 2025 Clinical Trial …
-
NiKang concludes first cohort dosing in Phase I trial of NKT3964 for tumours
NiKang Therapeutics has concluded the first cohort dosing in the open-label Phase I trial of NKT3964 as a monotherapy for …
-
Artificial intelligence is making clinical supply chains more efficient and more sustainable: here’s how
The pharmaceutical industry is in the midst of a digital revolution; technology investments and data-driven decision-making are constantly on the …
-
Mineralys’s stock soars as hypertension pill scores in two pivotal trials
Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, boosting the company’s stock price. The …
